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Background. Our aim was to assess both the credibility and strength of evidence arising from systematic reviews with meta-
analyses of observational studies and physical health outcomes associated with human immunodeficiency virus (HIV) but not ac-
quired immunodeficiency syndrome.
Methods. We performed an umbrella review of observational studies. Evidence was graded as convincing, highly suggestive, 
suggestive, weak, or nonsignificant.
Results. From 3413 studies returned, 20 were included, covering 55 health outcomes. Median number of participants was 18 743 
(range 403–225 000 000). Overall, 45 (81.8%) of the 55 unique outcomes reported nominally significant summary results (P < .05). 
Only 5 outcomes (9.0%; higher likelihood of presence of breathlessness, higher chronic obstructive pulmonary disease [COPD] 
prevalence, maternal sepsis, higher risk of anemia, and higher risk of all fractures among people living with HIV [PLWHIV]) showed 
suggestive evidence, with P values < 10–3; only 3 (5.5%; higher prevalence of cough in cross-sectional studies, higher incidence of 
pregnancy-related mortality, and higher incidence of ischemic heart disease among PLWHIV in cohort studies) outcomes showed 
stronger evidence using a stringent P value (<10–6). None of the unique outcomes presented convincing evidence (Class I), yet 3 out-
comes presented highly suggestive evidence, 5 outcomes presented suggestive evidence, and 37 outcomes presented weak evidence.
Conclusions. Results show highly suggestive and suggestive evidence for HIV and the presence of a cough, COPD, ischemic 
heart disease, pregnancy-related mortality, maternal sepsis, and bone fractures. Public health policies should reflect and accommo-
date these changes, especially in light of the increases in the life expectancy and the incidence of comorbidities in this population.
Keywords. HIV; human immunodeficiency virus; health outcomes; comorbid; umbrella review.
The incidence rates of human immunodeficiency virus (HIV) 
infection have shown a slow but steady decline over the past 
2 decades. Despite this decline, 1.8 million people globally are 
newly infected with HIV every year, which maintains HIV’s 
status as a top global health issue [1].
Globally, the most common cause of death in people living 
with HIV (PLWHIV) is tuberculosis [2]. However, in developed 
countries where tuberculosis is rare and there is high access to 
antiretroviral treatment (ART), diseases not related to acquired 
immunodeficiency syndrome (AIDS; including but not limited 
to diabetes mellitus, kidney disease, liver disease, hypertension, 
cardiovascular disease, and non–AIDS related malignancies) 
are a leading cause of death among PLWHIV who receive treat-
ment [3]. Correspondingly, the importance of non–AIDS re-
lated comorbidities, complications, and mortality has increased 
over the last decade [4].
Reasons for the rise in non–AIDS related morbidity is a 
question of some debate. In general, the availability of ART led 
to a substantial rise in the life expectancy of PLWHIV, which 
is now almost comparable to that of the general, seronega-
tive population and may be accompanied by more non–AIDS 
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related morbidity [5]. Studies have, however, reported greater 
prevalences of age-associated diseases in PLWHIV. This may be 
explained by the persistent immunodeficiency, immune activa-
tion, and chronic infection–associated inflammation connected 
with infection [6]. Additionally, ART itself may act directly, with 
reported adverse effects including hyperlipidaemia, insulin re-
sistance, and the proinflammatory effect of some nucleoside 
analogues [7, 8]. Lastly, PLWHIV in developed countries, as a 
population, often exhibit greater risk factors associated with in-
cidences of non–AIDS related illnesses, such as smoking, drug 
use, and alcohol use [5, 7, 9, 10].
Given the incidence, morbidity, and mortality rates associ-
ated with HIV, numerous systematic reviews and meta-analyses 
have attempted to quantify this disparate literature. To date, 
most systematic reviews have focused on a single disease end 
point and there has not been a systematic evaluation of the re-
lationships between HIV and diverse physical health outcomes. 
Moreover, the strength and reliability of the literature is unclear.
In order to address the breadth of the literature of complex 
health behaviors and outcomes, an increasing emphasis has 
been placed on “umbrella reviews” [11] (ie, the syntheses of 
existing systematic reviews with meta-analyses, to capture the 
breadth of outcomes associated with a given exposure). In this 
study, we undertook an umbrella review of existing systematic 
reviews with meta-analyses of HIV and all physical health out-
comes in order to systematically assess the quality and strength 
of the evidence across all health outcomes and to identify those 
studies with the strongest evidence.
MATERIALS AND METHODS
The protocol for the present umbrella review was preregistered 
with PROSPERO (registration number CRD42018107336).
An umbrella review was carried out following standardized 
procedures [11, 12]. Electronic databases were systematically 
searched via MEDLINE/PubMed, PsycINFO, and Embase from 
inception to 25 August 2018. The following search terms were 
used in MEDLINE/PubMed: “(meta-analysis or meta-anal* or 
systematic review) and (HIV or LAV or HTLV III or HTLV-
III or AIDS or human immunodeficiency virus or human 
T-lymphotropic virus III or acquired immunodeficiency).” In 
addition, we hand-searched the reference lists of eligible ar-
ticles and other narrative overviews of systematic reviews/
meta-analyses.
The primary screening was carried out by 2 authors (I. G. and 
L. Y.) and any disagreements were resolved via screening of the 
disputed title/abstract by a third author (N. V.). Full texts were 
sourced for all potential eligible articles and were screened by 2 
investigators (I. G. and L. Y.), who determined the final refer-
ences to be included.
We included systematic reviews with meta-analyses of obser-
vational studies (cross-sectional, case control, or retrospective 
and prospective cohort studies) that investigated the relation-
ship between HIV and any physical health outcomes. Specific 
inclusion criteria included: (1) systematic reviews with meta-
analyses reporting data on HIV (diagnosed through self-reports 
or laboratory confirmation); and (2) meta-analyses of cross-sec-
tional or cohort studies that investigated the association of HIV 
with any health outcome (eg, cardiovascular disease, cancer, 
obesity/overweight, diabetes, or metabolic diseases). Studies 
had to report these outcomes as odds ratios, relative risks (RRs), 
hazard ratios, or continuous data (standardized mean differ-
ence, weighted mean difference, or mean difference [MD]). 
Studies could have been published in any language. Studies 
were excluded if they were related to immunosuppression or re-
lated to correlates of HIV infection.
Data Extraction
The following information was extracted from each article by 
2 independent investigators: (1) first author name; (2) year of 
publication; (3) journal; (4) number of included studies and 
total number of people included in the review; (5) inclusion 
criteria for the studied population; (6) effect size(s) used in 
the review; (7) subgrouping used in the meta-analysis (with 
or without ART); (8) study design (case-control, retrospective, 
prospective); and (9) number of cases (ie, those having the out-
come of interest: eg, cancer) and controls (ie, those not having 
the outcome of interest: eg, no cancer) for each study. We then 
extracted the study-specific, estimated RR for the health out-
come (risk ratio, odds ratio, hazard ratio, standardized mean 
difference, weighted mean difference, MD), along with the 95% 
confidence interval (CI). If 2 meta-analyses were available for 
the same association, we included the largest in terms of the 
number of studies.
Risk of Bias (Quality) Assessment
Independently, 2 authors rated the methodological quality of 
the included meta-analyses using the AMSTAR 2 tool [13] (see 
Supplementary Table 1 for a full list of questions asked).
Data Analysis and Credibility Assessment
For each meta-analysis, we estimated the summary effect size 
and 95% CI through random-effects models [14]. In cases 
where the summary effect size of a meta-analysis was reported 
as MD, we transformed the metric to RR using an established 
formula [15]. We also estimated the prediction interval and its 
95% CI, which further accounted for between-study effects and 
estimated the certainty of the association if a new study ad-
dressed that same association [16–18]. For the largest data set of 
each meta-analysis, we calculated the standard error (SE) of the 
effect size. If the SE was less than 0.10, then the 95% CI would 
be lower than 0.20 (which is less than the magnitude of a small 
effect size). We also considered whether the largest study was 
significant (ie, P value  <  .05). The between-study association 
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was estimated with the I2 metric; values > 50% were indicative 
of high heterogeneity, while values above 75% suggest very high 
heterogeneity [19, 20].
In addition, we calculated the evidence of small-study ef-
fects (ie, whether small studies would have inflated effect sizes 
compared to larger studies). To this end, we used the regression 
asymmetry test developed by Egger and coworkers [21]. A  P 
value < .10, with more conservative effects in larger studies than 
in random-effects meta-analyses, was considered as indicative 
of small-study effects [22].
Finally, we applied the excess significance test [23], which 
evaluates whether the number of studies with nominally sig-
nificant results (ie, with P  <  .05) among those included in a 
meta-analysis is too large, based on the power that these data 
sets have to detect effects at α = .05. For this analysis, the power 
estimate for each data set was calculated. The sum of the power 
estimates of each study provided the expected number of data 
sets with nominal statistical significance. As described else-
where, the number of expected “positive” (ie, statistically sig-
nificant data sets) studies can be compared with the observed 
number of statistically significant studies through a χ 2-based 
test [23]. The larger the difference between the observed and 
expected number of significant studies, the higher the degree 
of excess of a significance bias. The true effect size of a meta-
analysis is unknown. We considered the effect size of the largest 
study for each meta-analysis (ie, with the lower SE) and, based 
on this, we estimated the effect sizes of each constituent study 
with an algorithm using a noncentral t distribution. The excess 
significance for a single meta-analysis was considered whenever 
the P value was < .10.
We used credibility assessment criteria (based on established 
tools for observational evidence, as summarized previously [24, 
25]) and classified the evidence of significant outcomes (P value 
in random effect model <.05) in 4 classes (Class I, convincing; 
Class II, highly suggestive; Class III, suggestive; Class IV, weak). 
Full details are given in Table 1.
RESULTS
As shown in Figure 1, the review of the literature identified 
3413 unique papers across 3 major databases. After applying 
the inclusion/exclusion criteria, 103 papers were identified and, 
of them, 20 were eligible. A total of 55 unique health outcomes 
were assessed across the 20 meta-analyses included in our um-
brella review.
Meta-analyses of Observational Studies
As reported in Supplementary Table 2, the median number of 
studies for each outcome in meta-analyses was 8 (range 2–42), 
the median number of participants was 18  743 (range 403–
225 000 000), and the median number of cases was 847 (range 
7–627 199). The diverse comorbidity outcomes included met-
abolic disorders, respiratory conditions, mortality, cardiovas-
cular conditions, cancer, and maternal and newborn outcomes.
Overall, for 45 (81.8%) of the 55 unique outcomes, there were 
nominally significant summary results (P < .05); among these, 
5 outcomes (9.0%) showed suggestive evidence, with P values < 
10–3, and 3 (5.5%) outcomes showed stronger evidence using a 
stringent P value (<10–6).
Heterogeneity among studies was generally high: 39/55 out-
comes (70.9%) had an estimated I2 consistent with large het-
erogeneity (>50%), with 26 showing very large heterogeneity 
(>75%). There were 5 outcomes that presented 95% prediction 
intervals, excluding the null value. The evidence for excess sta-
tistical significance (ie, whether smaller studies tend to give sub-
stantially larger estimates of effect size, compared with larger 
studies) was present in 17 outcomes (30.9%), and small-study 
effects were also seen in 16 of the outcomes (29.1%). Studies 
with the largest sample size for each outcome maintained their 
statistical significance in 38/55 outcomes (69.1%). Further, for 
15/55 outcomes (27.3%), the largest study had a more conserva-
tive effect, compared to the random-effects model.
Based on the above criteria, no outcome presented convincing 
evidence (Class I). There were 3 outcomes that presented highly 
suggestive evidence (Class  II: higher prevalence of cough in 
cross-sectional studies, higher incidence of pregnancy-related 
mortality, and higher incidence of ischemic heart disease 
among PLWHIV in cohort studies), 5 outcomes that presented 
suggestive evidence (Class III: higher likelihood of presence of 
breathlessness, higher chronic obstructive pulmonary disease 
[COPD] prevalence, maternal sepsis, higher risk of anemia, and 
higher risk of all fractures among PLWHIV; Tables 1 and 2), and 
Table 1. Credibility Assessment Criteria for Meta-analyses of Observational Studies
Evidence Classification Criteria
Convincing (Class I) Associations with P < .000001; >1000 cases (or >20 000 participants for continuous outcomes) having the event of 
interest; the largest component study reporting a nominal, statistically significant result (P < .05); a 95% predic-
tion interval that excluded the null; no large heterogeneity (I2 < 50%); no evidence of small-study effect (P > .10); 
no excess significance bias (P > .10).
Highly suggestive (Class II) Associations with P < .000001; >1000 cases (or >20 000 participants for continuous outcomes) having the event of 
interest; the largest component study reporting a statistically significant result (P < .05).
Suggestive (Class III) Associations with P < .001; >1000 cases (or >20 000 participants for continuous outcomes) having the event of 
interest.
Weak (Class IV) Remaining statistically significant associations with P < .05.
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37 outcomes that presented weak evidence. The 3 outcomes in 
Class II scored low or critically low according to the AMSTAR 2 
evaluation (Supplementary Table 1).
The majority of meta-analyses scored critically low (n = 15) 
on AMSTAR 2, and 4 scored low (Supplementary Table 1).
DISCUSSION
In this study, which included 20 meta-analyses and 55 different 
outcomes that are associated with HIV infection, we found highly 
suggestive evidence that HIV infection is associated with a higher 
presence of coughing in cross-sectional studies and higher risks 
of pregnancy-related mortality and ischemic heart disease in 
cohort studies. Suggestive evidence was found for a higher like-
lihood of the presence of breathlessness, a higher COPD preva-
lence, maternal sepsis, a higher risk of anemia, and a higher risk 
of all fractures among PLWHIV. These conclusions are based 
on the evaluation of epidemiological evidence credibility, which 
is a common approach used in a variety of research. Such crit-
ical appraisals of literature are necessary, as the nominal signifi-
cance level of P < .05 is widely used to claim new associations in 
literature. However, emerging evidence shows that results based 
on this criterion constitute weak evidence, as also confirmed by 
our umbrella review, where 45 outcomes were statistically signif-
icant (P <  .05) but no convincing evidence was evident: highly 
suggestive evidence was observed for only 3 outcomes.
We found highly suggestive evidence that HIV infection is as-
sociated with the presence of coughing and suggestive evidence 
for an association with the presence of breathlessness and the 
prevalence of COPD. These results indicate that, even with the 
high availability of ART, PLWHIV experience disproportion-
ally more chronic respiratory illness in comparison to seroneg-
ative populations [26]. This may be linked to the exponential 
rise in life expectancy for PLWHIV [27, 28], bringing about a 
population of aging PLWHIV that have higher prevalences of 
comorbidities and respiratory illnesses. Additionally, PLWHIV 
in resource-rich settings have higher prevalences of smoking 
and illicit drug use than seronegative people [9, 10, 29, 30], 
which are linked to higher respiratory and cardiovascular di-
sease incidences [31].
Studies included in 
umbrella review
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55 outcomes
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database searching in PubMed, 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart.
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Our analysis also showed highly suggestive evidence of the 
association between HIV infection and ischemic heart disease. 
Reasons for this include the aforementioned high prevalences 
of smoking and illicit drug use within this population, but may 
also be related to underlying, chronic inflammation and im-
mune activation, combined with coagulation abnormalities and 
atherosclerosis [32]. Overall, following the advent of ART, the 
mortality of PLWHIV attributable to cardiovascular disease is 
considerable [33]. Studies indicate that PLWHIV have a higher 
risk of cardiovascular disease, in comparison to seronegative 
people, with some earlier studies indicating an even higher 
risk among PLWHIV receiving protease inhibitors, in compar-
ison to therapy-naive PLWHIV [34, 35]. Reasons for this may 
be linked to “inflamm-aging”: a term that describes a chronic, 
low-grade inflammation characteristic of biological aging that 
shares similarities with the persistent immune activation ob-
served in PLWHIV [36–39]. The resulting immunosenesence 
coupled with “inflamm-aging” may predispose PLWHIV to 
comorbid conditions such as cardiovascular disease, metabolic 
and neurocognitive disorders, or cancer [37, 38, 40]. Reports on 
the specific pathophysiological processes leading to lung symp-
toms are rare, but may be explained by the reduced ability of 
alveolar macrophages to maintain homeostasis [41].
We report on highly suggestive and suggestive levels of ev-
idence concerning the association of HIV with pregnancy-
related mortality and sepsis, respectively. The pathological 
interactions between HIV infection and pregnancy-related out-
comes are poorly understood [42, 43]; however, given the high 
number of women living with HIV, with the highest proportion 
in resource-poor settings where there is a substantial risk of ma-
ternal mortality, there is an intersecting problem that poses a 
major public health issue [1]. Systematic reviews have found no 
evidence to support the idea that pregnancy somehow acceler-
ates HIV’s progression. Our analysis did show highly suggestive 
evidence to support the association of maternal HIV infection 
and pregnancy-related mortality. This may be explained by the 
generally poor health of women living with HIV, but may also 
be due to HIV-related thrombocytopenia, leading to excessive 
bleeding [44, 45]. Moreover, high levels of stigma and other so-
cial issues faced by women living with HIV might prevent or 
Table 2. Summarized Physical Health Outcomes and Evidence Class Reported in Included Meta-analyses of Observational Studies
Level of Evidence 
Outcome I II III IV NS
CVD None Cohort studies: risk 
of ischemic heart 
disease
None Cohort studies: risk of AMI, CAD, any 
stroke, ischemic stroke
Case-control studies: risk of 
coronary stenosis; risk of 
calcified plaques; risk of any 
plaque
Case-control studies: risk of 
noncalcified plaques 
 …
Case-control/cross-sectional studies: 
prevalence of IMT, flow-mediated 
vasodilatation, pulse wave velocity
 …
Gynecological 
outcomes
None Cohort studies: risk 
of pregnancy-
related mortality
None Cohort studies: risk of stillbirth, per-
inatal mortality, infant mortality, 
pregnancy-induced hypertension, 
caesarian sepsis, caesarian wound 
infection, caesarian endometritis, low 
birthweight, preterm delivery
Cohort studies: risk of neonatal 
mortality, pregnancy-related 
hypertension, pre-eclampsia, 
eclampsia, abnormal presen-
tation, caesarian section
Cohort/case-control studies: risk of 
uterine rupture, endometritis
 …
Metabolic and 
blood pressure 
outcomes
None None None Cohort studies: mean hemoglobin 
levels
 …
Cross-sectional/case-control studies: 
mean BMI, TGs, HDL, SBP, DBP 
levels
Cross-sectional/case-control 
studies: mean LDL, glucose, 
HbA1c levels
Other outcomes None Cross-sectional 
studies:  
prevalence of 
cough
Cohort studies: risk of  
fractures, sepsis, death
Cohort studies: risk of intracranial hem-
orrhage, renal disease, melanoma 
(pre- and post-HAART time period)
…
 … Case-control studies: risk of 
intracerebral hemorrhage
 …
Cross-sectional studies:  
prevalence of breathless-
ness, anemia, CPPD
Cross-sectional studies: prevalence 
of ED.
Cross-sectional/case-control 
studies: prevalence of dental 
caries
Abbreviations: AMI, acute myocardial infarction; BMI, body mass index; CAD, coronary artery disease; CPPD, calcium pyrophosphate dihydrate crystal deposition disease; CVD, cardiovas-
cular disease; DBP, diastolic blood pressure;  ED, erectile dysfunction; HAART, highly active antiretroviral therapy; HbA1c, glycated hemoglobin;  HDL, high-density lipoprotein; IMT, intima 
media thickness; LDL, low-density lipoprotein; NS, not significant; SBP, systolic blood pressure; TGs, triglycerides.
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inhibit their access to healthcare services [46, 47]. Lower im-
mune activation and suppression may be the underlying reason 
for the high susceptibility to infections and sepsis in women 
living with HIV, with the latter showing a suggestive level of 
evidence in our analysis [48, 49].
The final 2 outcomes showing suggestive levels of evidence 
in our analysis were the risk of anemia in children and the risk 
of bone fractures. For both outcomes, the mechanisms remain 
unclear. While anemia has been reported to be among the most 
common hematological complications to follow HIV infec-
tion, bone fractures have not been as commonly reported. The 
literature suggests effects of HIV on erythrocyte production in 
cases of anemia [50], while the effects on bone loss and fractures 
seem to be less clear, with most studies reporting diverse vari-
ables that may have synergistic effects, such as tobacco smoking, 
drug use, low body weights, low CD4+ cell counts, and hepatitis 
C coinfections [51].
Umbrella reviews provide top-tier evidence and important 
insights, but there are a number of limitations that need to be 
considered. The meta-analyses contained studies that differed in 
their designs, populations, and other characteristics. However, 
we applied an I2 <50% as 1 of the criteria for Class I evidence 
(convincing), in order to assign the best evidence grade only to 
robust associations. Second, many studies in our umbrella re-
view determined individuals’ HIV statuses using self-reported 
information, but the agreement between self-reported and bio-
humoral diagnoses is often poor [52]. Finally, meta-analyses 
have inherent limitations [53]: their findings depend on which 
estimates are selected from each primary study and how they 
are applied in the meta-analysis.
CONCLUSION
Our results show highly suggestive and suggestive evidence 
for links between HIV and the presence of coughs, prevalence 
of COPD, incidence of ischemic heart disease, incidence of 
pregnancy-related mortality, incidence of maternal sepsis, and 
risk of bone fractures. Public health policies should reflect and 
accommodate these changes, especially in light of the increases 
in both life expectancy and incidences of comorbidities in this 
population. The elevated risks of the reported outcomes re-
quires more research to improve both the prevention and early 
detection of these comorbidities in PLWHIV.
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